

1 ***DPYD* genetic polymorphisms in non-European patients**
2 **with severe fluoropyrimidine-related toxicity: A**
3 **systematic review**

4
5 Tsun Ho Chan^{*1}, J. Eunice Zhang^{*1}, Munir Pirmohamed¹

6
7 ¹Wolfson Centre for Personalised Medicine, Department of Pharmacology and
8 Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of
9 Liverpool, 1-5 Brownlow Street, Liverpool, L69 3GL, UK

10
11 *These authors contributed equally to this work.

12
13 Correspondence: Professor Sir Munir Pirmohamed, Wolfson Centre for Personalised
14 Medicine, Institute of Systems, Molecular and Integrative Biology, University of
15 Liverpool, 1-5 Brownlow Street, Liverpool, L69 3GL, UK.
16 Email: munirp@liverpool.ac.uk

17
18 Funding: This work is supported by the NHS Race & Health Observatory.

19
20 **Keywords:** *DPYD*; DPD, dihydropyrimidine dehydrogenase; genetic variant;
21 polymorphism; haplotype; pharmacogenetics; pharmacogenomics; fluoropyrimidine; 5-
22 fluorouracil; capecitabine; tegafur; chemotherapy; severe toxicity; adverse reactions; side
23 effects

44 **Abstract**

45

46 **Background:** Pre-treatment *DPYD* screening is mandated in the UK and EU to reduce the
47 risk of severe and potentially fatal fluoropyrimidine-related toxicity. Four *DPYD* gene
48 variants which are more prominently found in Europeans are tested.

49

50 **Methods:** Our systematic review in patients of non-European ancestry followed PRISMA
51 guidelines to identify relevant articles up to April 2023. Published *in silico* functional
52 predictions and *in vitro* functional data were also extracted. We also undertook *in silico*
53 prediction for all *DPYD* variants identified.

54

55 **Results:** In 32 studies, published between 1998 and 2022, 53 *DPYD* variants were
56 evaluated in patients from 12 countries encompassing 5 ethnic groups: African American,
57 East Asian, Latin American, Middle Eastern, and South Asian. One of the 4 common
58 European *DPYD* variants, c.1905+1G>A, is also present in South Asian, East Asian and
59 Middle Eastern patients with severe fluoropyrimidine-related toxicity. There seems to be
60 relatively strong evidence for the c.557A>G variant, which is found in individuals of
61 African ancestry, but is not currently included in the UK genotyping panel.

62

63 **Conclusion:** Extending UK pre-treatment *DPYD* screening to include variants that are
64 present in some non-European ancestry groups will improve patient safety and reduce race
65 and health inequalities in ethnically diverse societies.

66

67

68

69 **Introduction**

70 Fluoropyrimidines are antimetabolite chemotherapy drugs comprising the
71 parenterally administered 5-fluorouracil (5-FU) and its prodrugs, capecitabine and tegafur.
72 They are commonly used either as monotherapy or in combination with other antineoplastic
73 agents in neo-adjuvant, adjuvant and palliative settings for a variety of solid tumour types
74 including colorectal, breast, oesophago-gastric and head and neck cancers^{1,2}. 5-FU and
75 capecitabine have been on the World Health Organization (WHO) Essential Medicines List
76 (EML) since 1977 and 2015, respectively^{3,4}. Annually, over two million patients worldwide
77 and approximately 600,000 patients in Europe receive treatment with fluoropyrimidines⁵⁻⁷.
78 Due to a narrow therapeutic index, 10-30% of patients who receive standard
79 fluoropyrimidine doses develop severe toxicity including bone marrow suppression,
80 diarrhoea, mucositis and hand-foot syndrome, usually within the first 1-2 cycles of treatment
81⁸⁻¹¹. Severe fluoropyrimidine-related toxicity leads to mortality in approximately 0.5-1% of
82 patients (with up to 5% lethal toxicity reported in elderly patients)¹²⁻¹⁶.

83 Development of toxicity is in part due to inter-individual variability in
84 dihydropyrimidine dehydrogenase (DPD) activity. The first case report of a patient
85 presenting with 5-FU-related severe toxicity due to DPD deficiency was in 1985¹⁷. DPD is
86 the primary enzyme responsible for the catabolism and elimination of >80% of the
87 administered 5-FU to the inactive metabolite dihydrofluorouracil (DHFU)^{1,15,18,19}.
88 Deficiency of the DPD enzyme, either complete or partial, leads to inadequate clearance of
89 5-FU which increases drug exposure and accumulation, increasing the risk of severe and
90 sometimes fatal toxicity²⁰⁻²². DPD deficiency can be detected in 39–61% of patients with
91 severe fluoropyrimidine-related toxicity²³. In individuals of European ancestry, the
92 frequency of partial DPD enzyme deficiency ranges from 3 to 5% while complete DPD
93 enzyme deficiency is less frequent, with an estimated prevalence of 0.1-0.2%^{24,25}.

94 The DPD gene (*DPYD*) is expressed in a wide variety of human tissues; high levels
95 are observed in the liver and peripheral blood mononuclear cells (PBMCs)^{26,27}. Located on
96 chromosome 1p21.3, *DPYD* is a large pharmacogene spanning ~920 kb in length, with 23
97 relatively small exons (69-961 bp) surrounded by large intronic regions^{28,29}. The coding
98 sequence totals ~3 kb in length and encodes a polypeptide comprising 1,025 amino acid
99 residues^{28,29}. *DPYD* is highly polymorphic: the Genome Aggregation Database (gnomAD
100 v2.1.1) includes 204 synonymous variants and 569 missense variants, 40 of which are
101 predicted to lead to loss of enzymatic function³⁰.

102 The latest version of the Clinical Pharmacogenetics Implementation Consortium
103 (CPIC) guideline includes 82 known *DPYD* variants, among which, 21 are considered to
104 have no DPD function and 6 to have diminished DPD function⁶. Prospective genotyping of
105 *DPYD* can identify patients with DPD enzyme deficiency and allow for prophylactic
106 fluoropyrimidine dose adjustments, thereby reducing the likelihood of fluoropyrimidine-
107 related toxicity without compromising cancer treatment effect³¹⁻³⁵.

108 In June 2020, the European Medicines Agency (EMA) recommended DPD testing
109 either by phenotyping or genotyping prior to treatment with fluoropyrimidines³⁶. In
110 November 2020, the National Health Service (NHS) commissioned *DPYD* genetic testing
111 making this one of the first pharmacogenomic tests to be applied nationally in the UK³⁷. A
112 variety of genotyping methods are used by the labs but they all test for the four pathological
113 *DPYD* variants commonly described in Europeans:

- 114 • c.1905+1G>A (IVS14+1G>A, rs3918290, *DPYD* *2A), a splice-site variant causing
115 exon 14 skipping which results in the production of an inactive protein^{38,39};
- 116 • c.2846A>T (p.Asp949Val, rs67376798, *DPYD**9B), a non-synonymous variant that
117 leads to reduced DPD activity;
- 118 • c.1236G>A/HapB3 (p.Glu412=, rs56038477), a synonymous variant which tags for
119 c.1129-5923C>G (rs75017182), a deep-intronic splice-site variant causing significant
120 loss of DPD activity, which is in near perfect linkage disequilibrium (LD) with the
121 *DPYD* haplotype HapB3 encompassing three intronic variants (rs56276561,
122 rs6668296, rs115349832); and
- 123 • c.1679T>G (p.Ile560Ser, rs55886062, *DPYD**13), a missense variant causing
124 decreased DPD activity.

125 This is because the three key clinical studies which provided evidence for the clinical utility
126 of *DPYD* testing to reduce the incidence of severe fluoropyrimidine-related toxicity were
127 all undertaken in European populations^{11,31,32}. The minor allele frequencies (MAF) of these
128 four prominent European *DPYD* variants across non-European population groups from the
129 1000 Genomes Project Phase 3⁴⁰ and gnomAD v3.1.2 and v4.0.0⁴¹ databases are shown in
130 Supplementary Table 1.

131 It is known that there are inter-ethnic differences in *DPYD* variant frequency. In fact,
132 several studies have reported the absence of the European *DPYD* variants in populations
133 from East and Southern Africa, namely Somalia, Kenya⁴² and Zimbabwe⁴³, and East Asia
134 including China⁴⁴ and Japan⁴⁵⁻⁴⁸. In addition, variants that are not present in Europeans can
135 have a profound impact in non-European populations, and vice versa⁴⁹. Hence, the testing

136 being undertaken by EU countries and the UK NHS will not identify genetic variants in
137 non-European populations, who will be treated as wild-type, and given conventional doses
138 of the fluoropyrimidine drugs, with the likelihood of toxicity, and in the worst-case scenario,
139 death. This has the potential to exacerbate health and race inequalities in ethnically diverse
140 societies. Furthermore, it does not help countries where the population is predominantly of
141 non-European ancestry, as *DPYD* genetic testing will not be implemented because of lack
142 of evidence. It is crucial that all global populations benefit equally from this important
143 genetic test. We have therefore undertaken a systematic review to evaluate *DPYD* genetic
144 variants which have been reported in patients of non-European ancestry who developed
145 severe fluoropyrimidine-related toxicity.

146

147 **Methods**

148 **Design and registration**

149 A systematic review was conducted in accordance to the Preferred Reporting Items
150 for Systematic reviews and Meta-Analyses (PRISMA) 2020 guideline⁵⁰. The review
151 protocol was registered in the PROSPERO repository of systematic reviews (registration
152 number CRD42023385227). The EndNote™ X9 software was used to manage all articles
153 (both included and excluded records) throughout the research process.

154

155 **Search strategy**

156 A literature search was performed using the MEDLINE (PubMed), Web of Science,
157 Embase (OVID) and Scopus electronic databases to identify relevant articles published prior
158 to 04 April 2023. The search strategy employed a combination of MeSH terms and
159 keywords using the Boolean operators “AND” and “OR”. In addition, syntax adjustments
160 were made appropriate to each database. The search terms used in the MEDLINE (PubMed)
161 search are described in Supplementary Table 2; similar terms were used in the Web of
162 Science, Embase (OVID), and Scopus searches.

163

164 **Eligibility criteria**

165 We limited our search to clinical research studies, case series and case reports that
166 genotyped for *DPYD* genetic variants in patients of non-European ancestry who had
167 developed severe fluoropyrimidine-related toxicity after chemotherapy treatment
168 containing 5-FU, capecitabine or tegafur. We accepted the definition of severe toxicities as
169 (1) grade ≥ 3 severe adverse events according to the Common Terminology Criteria for

170 Adverse Event (CTCAE) ⁵¹, (2) grade ≥ 3 severe adverse events in accordance to the World
171 Health Organization (WHO) ⁵², and (3) dose-limiting toxicity (DLT) which is defined as
172 pre-specified severe adverse events of grade 3 or higher based on the CTCAE classification.
173 In order to maximise the number of included studies, we also accepted author-defined
174 severity grading of fluoropyrimidine-related toxicities where terms ‘grade 3’, ‘grade ≥ 3 ’,
175 ‘grade 4’, or ‘severe’ were used but no classification tool was specified.

176 Only publications with full text availability were included. Publications in all
177 languages were assessed with non-English articles translated either via Google Translate or
178 with assistance from colleagues who were native speakers of the foreign language. Authors
179 and titles of conference meeting abstracts were used to check whether full-text articles had
180 been published. Editorials, opinion letters, and unrefereed preprints were not considered.

181

182 **Screening process and study selection**

183 After study duplications were removed, T.H.C screened the titles and abstracts of all
184 articles in accordance with the above eligibility criteria to identify the relevant studies for
185 first phase inclusion; irrelevant studies were excluded. In the second phase of the review
186 process, full-text articles of the relevant studies were retrieved, and in-depth full-text
187 screening was carried out. Detailed full-text screening also included the inspection of all
188 cited references. In addition, the reference lists of clinical guidelines, policy statements from
189 regulatory agencies, pertinent narrative and systematic reviews were also screened to check
190 for additional eligible studies. In the situation of any uncertainty during the selection
191 process, the full text was checked and resolved by consensus with J.E.Z.

192

193 **Quality assessment**

194 T.H.C and J.E.Z independently assessed the methodological quality of each included
195 study and relied on peer-review to ensure included studies were methodologically sound. A
196 formal assessment of the risk of bias was not undertaken.

197

198 **Data extraction**

199 Relevant summary and patient-level data from published manuscripts and appendix
200 materials of included studies were independently extracted by T.H.C and J.E.Z. A data
201 extraction form was compiled and data items collected are detailed in the Supplementary
202 Methods. For studies which included patients of European and non-European ancestries,
203 only data reported for non-Europeans were extracted. In instances where information

204 provided in the published manuscript was unclear, we contacted the study authors by email
205 for clarification but amongst the six emails sent out, no response was received, and therefore
206 these 6 articles were excluded. If the exact number for a data item could not be extracted,
207 meticulous estimation was undertaken where possible. All extracted data were presented
208 and compared between T.H.C and J.E.Z, with any disagreements resolved by discussion to
209 reach consensus.

210

211 **Data synthesis**

212 Due to the heterogeneity of articles included in this systematic review and the small
213 number of studies conducted in each ethnicity, it was impossible to perform a quantitative
214 analysis, and so the findings are described in a narrative way and data extracted from each
215 article presented in tables. No meta-analysis was undertaken.

216

217 ***In silico* prediction**

218 *In silico* prediction was undertaken for all *DPYD* genetic variants evaluated in this
219 systematic review and is described in the Supplementary Methods. The scoring thresholds
220 and software weblinks of the *in silico* prediction tools used are summarised in
221 Supplementary Table 3.

222

223 **Published *in silico* functional predictions and *in vitro* functional data**

224 To acquire a more nuanced understanding of the *DPYD* variants identified in our
225 systematic review, published data from previously developed *in silico* functional prediction
226 models with high accuracy, the *DPYD*-varifier⁵³ and the ADME-optimised Prediction
227 Framework (APF)^{54,55}, were extracted (described in Supplementary Methods). In addition,
228 functional data on DPD enzyme activity from *in vitro* experiments where HEK293T/c17,
229 HEK293-Flp-In and 293FT cells were transiently expressed with *DPYD* variants and treated
230 with either 5-FU or thymine were extracted^{42,45,56-59}.

231

232 **Results**

233 **Identification and selection of articles**

234 A detailed flow diagram showing the identification and selection process for study
235 inclusion, according to the PRISMA statement, is depicted in Figure 1. All articles included
236 were in English; none of the non-English articles met the criteria for inclusion.

237

238 **Characteristics of included articles**

239 Table 1 details the 32 included articles and a summary breakdown of the
240 characteristics is provided in Supplementary Table 4. All articles were published between
241 September 1998 and December 2022. Two studies were case series, 10 studies were case
242 reports and 20 were cohort studies with an equal split between prospective and retrospective
243 study designs. Patients were from 12 countries encompassing 5 ethnic groups: African
244 American (United States), East Asian (China, Japan, Korea, Thailand), Latin American
245 (Chile), Middle Eastern (Jordan, Lebanon, Saudi Arabia, Tunisia), and South Asian
246 (Bangladesh, India, United States).

247 Heterogeneity was present across the 32 articles included and are described in the
248 Supplementary Results.

249

250 **Patient characteristics**

251 A summary of the patient characteristics is presented in Table 2. A total of 1431
252 patients were included across the 32 studies. Their age ranged between 15 to 90 years, and
253 slightly more men than women were enrolled in most studies. The most common type of
254 tumour was colorectal cancer and most patients received either 5-FU or capecitabine-based
255 combination chemotherapy treatment that included oxaliplatin. All patients were reported
256 to have experienced grade 3 or higher fluoropyrimidine-related toxicities (as defined above).
257 Clinical manifestations included haematological, gastrointestinal, dermatological, hepatic,
258 neurological, and renal toxicities, with many with neutropenia, myelosuppression,
259 diarrhoea, mucositis and hand-foot-syndrome.

260

261 ***DPYD* genetic variants, haplotypes and *in silico* predictions**

262 Across the 32 included studies, a total of 53 *DPYD* genetic variants were reported,
263 of which 20 have been reported in the CPIC guideline⁶ (Figure 2). Genotype counts of
264 variants reported in patients with severe fluoropyrimidine-related toxicity across the 5
265 ethnicities with details of all extracted data items are presented in Supplementary Table 5.
266 Our *in silico* prediction results for all 53 *DPYD* variants identified are summarised in Table
267 3 with scores obtained from each *in silico* prediction tool detailed in Supplementary Table
268 6. In addition, 13 studies reported a combination of *DPYD* genetic variants at individual
269 patient-level and we were able to identify 26 haplotype combinations as presented in
270 Supplementary Table 7. Subsequent paragraphs in this section will focus on variants which
271 were reported in more than 1 individual in each ethnicity with either: (1) CPIC-reported

272 decreased or loss of DPD enzyme function or (2) unreported DPD enzyme function in the
273 CPIC guideline but predicted to be deleterious by >60% of the *in silico* tools we utilised.
274 Variants which were excluded due to this filtering process and haplotype combinations are
275 described in the Supplementary Results.

276

277 ***African American***

278 19 *DPYD* variants (2 missense, 2 frameshift, 11 intronic, one 5'-upstream, one
279 3'UTR, two 3'-downstream) were reported across 3 case studies⁶⁰⁻⁶² and 1 cohort study⁶³
280 conducted in patients of African American ancestry in the United States (Supplementary
281 Table 5).

282 Heterozygous carriage of the missense variant c.557A>G (Tyr186Cys) was reported
283 in all 3 case studies^{60,62,64}. This variant has a mean prevalence of ~2% in reference
284 populations of African descent (Supplementary Table 1)^{40,41} and the presence of either 1 or
285 2 copies of the c.557A>G variant allele is considered to cause a decrease in DPD enzyme
286 function (intermediate metaboliser) by the CPIC guideline with moderate strength of
287 evidence. Up to 77% of the *in silico* prediction tools we utilised predicted this variant to be
288 deleterious or probably damaging and this variant was classified as deleterious by APF
289 (Table 3). *In vitro* functional analysis containing the Tyr186Cys amino acid substitution
290 showed a ~15% reduction in DPD enzyme activity relative to the wild-type (Table 3)^{57,65}.
291 Maharjan and colleagues (2019) did not include c.557A>G genetic testing in their cohort of
292 African American patients⁶³.

293

294 ***East Asian***

295 A total of 30 *DPYD* variants (2 nonsense, 15 missense, 3 synonymous, 2 splice
296 donor, and 8 intronic) were reported in patients of East Asian ancestry which included 5
297 cohort studies⁶⁶⁻⁷⁰, 2 case reports from China^{71,72}, 2 cohort studies^{46,48}, 3 case reports from
298 Japan⁷³⁻⁷⁵, 1 cohort study from Korea⁷⁶, and 1 cohort study from Thailand⁷⁷
299 (Supplementary Table 5).

300 Amongst the 30 variants identified, 15 have been reported in the CPIC guideline
301 including 3 loss of function variants, c.1156G>T (Glu386Ter), c.1774C>T (Arg592Trp) and
302 c.1905+1G>A, with moderate, weak, and high strength of evidence respectively.
303 Heterozygous carriers of 1 of these 3 variants lead to decreased enzyme function and are
304 classified as intermediate metabolisers by CPIC; while homozygous carriers of either of
305 these 3 variants lead to loss of enzyme function and are classified by CPIC as poor

306 metabolisers. In reference populations of East Asian descent, these 3 variants are rare with
307 zero MAF observed for c.1156G>T and c.1905+1G>A, and a MAF of 0.1% for c.1774C>T
308 (Supplementary Table 1) ^{40,41}.

309 Heterozygous carriage of the truncating c.1156G>T variant was reported in three
310 Japanese patients, two from case reports who both exhibited >10 fold decrease in PBMC
311 DPD enzyme activity in comparison to normal/healthy individuals ^{74,75}, and one from a
312 cohort study where heterozygous carriage of 1 of the 7 rare pathogenic *DPYD* variants,
313 c.596G>A, c.733A>G, c.914C>A, c.1156G>T, c.1666A>C, c.1712C>A, or c.1863G>T
314 was significantly associated with grade 3-4 toxicity in comparison to patients without the 7
315 rare variants (OR = unreported; $p = 0.0271$; Supplementary Table 5) ⁴⁸. 100% of the *in silico*
316 prediction tools we utilised predicted c.1156G>T to be deleterious and published *in vitro*
317 expression analysis reported complete loss of DPD enzyme activity (Table 3) ^{57,65}.

318 Two patients, one from a Korean cohort study and one from a Thai cohort study,
319 were heterozygous for the nonsynonymous variant c.1774C>T ^{76,77}. Up to 92% of the *in*
320 *silico* prediction tools we utilised predicted c.1774C>T to be deleterious and the APF
321 classified this variant as deleterious (Table 3). Previously published *in vitro* functional
322 characterization of c.1774C>T reported a reduction in DPD catalytic activity compared to
323 the wild-type (Table 3) ^{45,57,59,65}.

324 Heterozygous carriers of the intron 14 splice donor variant c.1905+1G>A were
325 reported in one Thai cohort patient ⁷⁷ and 14 Chinese cohort patients in which significantly
326 higher incidences of grade 3-4 myelosuppression, hand-foot syndrome, diarrhoea,
327 gastrointestinal reactions and mucositis were observed (OR = unreported; $p < 0.001$ for each
328 severe side effect) compared to wild-type carriers ⁶⁹. 100% of the *in silico* prediction tools
329 we utilised predicted this variant to be deleterious and published *in vitro* expression analysis
330 reported c.1905+1G>A to be catalytically inactive (Table 3) ^{56,65}.

331 Two Chinese patients from a cohort study, one with grade 4 bone marrow inhibition
332 (BMI) and one with grade 4 BMI and grade 4 gastrointestinal toxicity, were reported to be
333 heterozygous carriers for the nonsense variant, c.464T>A (Leu155Ter). This variant is not
334 reported in the CPIC guideline. The DPD enzyme activity in PBMCs from both patients
335 was ~45% lower than that in non-carriers with Grade 1-2 toxicity (Supplementary Table 5)
336 ⁷⁰. In addition, when c.464T>A was analysed in composite with c.85T>C and c.2194G>A,
337 the carriage of either c.464T>A, c.85T>C, and/or c.2194G>A was associated with an
338 increased incidence of bone marrow toxicity (OR = 24; $p = 0.0001$) and gastrointestinal
339 toxicity (OR = 8; $p = 0.0019$) in comparison to non-variant carriers (Supplementary Table

340 5) ⁷⁰. 70% of the *in silico* prediction tools we used predicted the c.464T>A to be deleterious
341 (Table 3, Supplementary Table 6). No allele frequency information in reference populations
342 of East Asian descent and other ancestries has been reported for this variant (Supplementary
343 Table 1) ^{40,41}.

344

345 ***Latin American***

346 Only 1 cohort study from Chile was identified in the Latin American population ⁷⁸
347 and the authors examined 3 missense *DPYD* polymorphisms considered to have normal
348 DPD enzyme function by the CPIC guideline, c.85T>C, c.496A>G and c.1627A>G
349 (Supplementary Table 5, Supplementary Results).

350

351 ***Middle Eastern***

352 13 *DPYD* variants (1 splice donor, 8 missense, 4 intronic) were reported in patients
353 of Middle Eastern ancestry. There were 2 cohort studies from Tunisia ^{79,80}, 1 cohort study
354 from Jordan ⁸¹ 1 case report from Lebanon ⁸² and 1 case series from Saudi Arabia ⁸³
355 (Supplementary Table 5). None of the variants passed our filtering process (Supplementary
356 Results).

357

358 ***South Asian***

359 7 *DPYD* variants (6 missense, 1 splice donor) were reported in patients of South
360 Asian ancestry across 5 cohort studies from India ⁸⁴⁻⁸⁸, one Indian case series ⁸⁹, one case
361 study of an Indian patient in the USA ⁹⁰, and 1 cohort study from Bangladesh ⁹¹
362 (Supplementary Table 5).

363 With a prevalence of 0.3-1.5% in reference populations of South Asian descent
364 (Supplementary Table 1) ^{40,41}, the splice donor variant c.1905+1G>A was reported in
365 patients from Bangladesh and India ^{84,85,87-89,91}. The Bangladeshi cohort study reported a
366 significant association with anaemia (OR = 4.7, $p = 0.042$), neutropenia (OR = 6.47, $p =$
367 0.018), thrombocytopenia (OR = 8.08, $p = 0.05$), nausea (OR = 10.06, $p = 0.012$), and
368 diarrhoea (OR = 5.76, $p = 0.026$) when patients with grade 3-4 toxicities were compared to
369 patients with grade ≤ 2 toxicities ⁹¹. The Bangladeshi cohort study genotyped for only the
370 c.1905+1G>A variant, and whether there were other mutations was not investigated. One
371 of the four Indian cohort studies reported a decreased incidence of mucositis ($p = 0.016$)
372 and diarrhoea ($p = 0.006$) in *DPYD* variant carriers of either c.85T>C, c.496A>G,

373 c.1627A>G, c.1905+1G>A and/or c.2194G>A after 50% capecitabine dose reduction in
374 cycle 2 of chemotherapy ⁸⁷.

375

376 **Discussion**

377 This systematic review has identified numerous variants in the *DPYD* gene which
378 have been reported in non-European individuals with severe toxicity associated with the use
379 of fluoropyrimidines. In the UK and EU, testing for 4 *DPYD* genetic variants is undertaken
380 before the use of fluoropyrimidines ^{36,37} – in England, we currently do 38,000 tests per year.
381 This is an important success story for the implementation of pharmacogenomics, but there
382 is still a need to improve the testing pathway, both in terms of increasing the number of
383 genetic variants tested, and ensuring that we are not disadvantaging particular ethnic groups.

384 It is interesting to note that our systematic review has identified 3 of the 4 *DPYD*
385 variants tested in the UK and EU^{36,37}, in non-European individuals. The c.1905+1G>A
386 variant, which leads to exon 14 skipping, has been reported in 1 Thai ⁷⁷, 14 Chinese ⁶⁹, 1
387 Lebanese ⁸², 7 Bangladeshi ⁹¹ and 18 Indian ⁸⁴⁻⁸⁹ patients with fluoropyrimidine-related
388 toxicity. The frequency of this variant is 0% in East Asian reference populations, 0.3% in
389 Middle Eastern reference populations, and 0.3-1.5% in South Asian reference populations
390 ^{40,41}. The c.1679T>G and c.1236G>A/HapB3 variants have been reported in 1 Tunisian
391 patient ⁸⁰ and 1 Thai patient ⁷⁷, respectively. The prevalence of c.1679T>G is 0% in Middle
392 Eastern reference populations ⁴¹ and the frequency of c.1236G>A/HapB3 ranges from 0.01-
393 0.1% in East Asian reference populations ⁴¹. According to the 2021 UK census ⁹², South
394 Asians, East Asians, and Arabs represent 6.7%, 1.3%, and 0.6% of the UK population,
395 respectively, and thus they will benefit from the genetic testing which is offered to all
396 patients in the UK if they require treatment with 5-FU or its analogues.

397 Clearly, there are other variants in these ethnic groups which need further
398 investigation. For example, in South Asians and Middle Easterners, our systematic review
399 identified single occurrence of missense variants c.704G>A (p.Arg235Gln, rs755416212)
400 ⁹⁰ and c.257C>T (p.Pro86Leu, rs568132506) ⁸³, respectively. These variants are not
401 reported in the CPIC guideline but are predicted to be deleterious by >80% of the *in silico*
402 tools we used, with one research study reporting significant reduction of DPD activity *in*
403 *vitro* with the c.257C>T variant ⁴². Further functional work and greater interrogation of
404 patients who have had toxicity is warranted to confirm these findings and to identify other
405 functionally relevant variants.

406 It is important to briefly consider some other variants. First, c.464T>A (p.Leu155Ter,
407 rs2101026231), a nonsense variant, located on exon 5, causes the replacement of leucine
408 155 by a stopping codon, resulting in a truncated protein. This variant was first reported in
409 a Spanish patient who died from severe, multi-system toxicity following the first
410 administration of 5-FU for adjuvant colon cancer therapy⁹³. Two Chinese patients with 5-
411 FU-related severe toxicity who both patients exhibited ~45% lower DPD enzyme activity
412 in PBMCs compared to non-carriers have also been reported⁷⁰. This variant is not included
413 in the current CPIC guideline and its allele frequency across global ethnic populations in
414 the 1000 Genomes and gnomAD databases is currently unknown, but our *in silico* analysis
415 predicted this variant to be deleterious or probably damaging but further *in vitro* functional
416 work is required to confirm the impact of this variant on DPD enzyme activity. Second, the
417 exon 11 truncating variant, c.1156G>T (p.Glu386Ter, rs78060119, *12), leads to premature
418 protein truncation at amino acid position 386 and is classified as a loss-of-function variant
419 with moderate evidence level by the CPIC guideline. Heterozygous carriage of this variant
420 was detected in three Japanese patients with severe fluoropyrimidine-related toxicity across
421 2 case studies and 1 cohort study identified in our systematic review^{48,74,75}. *In vivo* and *in*
422 *vitro* studies of this variant observed over 90% reduction in DPD activity^{57,74,75}. Currently,
423 there is no guideline or mandate for *DPYD* testing before fluoropyrimidine treatment in
424 Japan but *DPYD* genetic testing that includes the c.1156G>T variant is available in several
425 hospital pharmacies and can be requested by the attending physician. Data from the latest
426 gnomAD release (v4.0) showed very low prevalence (<0.005%) of this variant across East
427 Asian, Admixed American, South Asian, and European populations. Third, the c.1774C>T
428 (p.Arg592Trp, rs59086055) variant has a prevalence of 0.1% in East Asian reference
429 populations^{40,41}; heterozygous carriage of c.1774C>T was detected in 1 Korean patient⁷⁶
430 and 1 Thai patient⁷⁷ in our systematic review. This exon 14 missense variant causing
431 Arg592Trp substitution is considered a loss-of-function variant by the CPIC guideline with
432 weak evidence. No *in vivo* data have been published for this variant but *in vitro* functional
433 work reported over 90% reduction in DPD activity^{45,57,59,65}. These variants seem to be
434 important but further work is required both to understand the functional relevance of these
435 variants, and identify other variants in East Asian individuals, to improve the prediction of
436 fluoropyrimidine-related toxicity in the different ethnic groups that constitute East Asian
437 populations in the UK and globally.

438 Our systematic review has identified 3 case studies detecting the c.557A>G variant
439 (rs115232898, p.Tyr186Cys) in African Americans with severe 5-FU-related toxicity⁶⁰⁻⁶²,

440 one of which was fatal ⁶¹. In addition, in an editorial which was not eligible for inclusion in
441 our systematic review, this variant was reported in an African-Caribbean patient with severe
442 5-FU-related toxicity ⁹⁴. This is a nonsynonymous variant located on exon 6 where carriers
443 have 46% lower DPD enzyme activity in PBMCs than non-carriers ⁹⁵. *In vitro* functional
444 analysis of DPD containing the Tyr186Cys amino acid substitution has shown a ~15%
445 reduction in DPD activity relative to wildtype ⁵⁷. Data from the 1000 Genomes Project Phase
446 3 confirms that c.557A>G is mainly found in African populations (Afro-Caribbeans in
447 Barbados, African Americans in southwest United States, Yoruba in Ibadan (Nigeria),
448 Luhya in Webuye (Kenya), Gambian in Western Divisions in the Gambia, Mende in Sierra
449 Leone, and Esan in Nigeria), with allele frequency ranging between 1-4% ⁴⁰. This variant is
450 virtually non-existent in Europeans, East Asians and South Asians. In the United States, the
451 Mayo Clinic and several commercial laboratories includes c.557A>G in their pre-treatment
452 *DPYD* testing to identify individuals at increased risk of toxicity when considering
453 fluoropyrimidine chemotherapy treatment. However, this variant is currently not included
454 in the UK NHS *DPYD* genetic testing. In the 2021 UK Census, 4% (2.4 million) of the total
455 population in England and Wales identified their ethnic group within the "Black, Black
456 British, Black Welsh, Caribbean or African" category ⁹².

457 Our systematic review also shows that few novel variants in the *DPYD* gene have
458 been reported in Middle Eastern ⁸¹ populations with a paucity of data in Latin American
459 populations ⁷⁸, highlighting the need for more studies in these populations. Indeed, further
460 studies are needed in all populations (European and non-European) to fully understand the
461 spectrum of harmful mutations which occur in this gene. This will require careful
462 identification and assessment of patients with toxicity caused by 5-FU or its analogues, and
463 subsequent sequencing of the *DPYD* gene together with functional characterisation of any
464 mutations identified. To this end, we have initiated a programme of work (called "DPYD-
465 International") which has the aim to identify affected patients globally so that evidence can
466 be generated to optimise the pathway for *DPYD* genetic screening to maximise benefits for
467 all populations and minimise any unintended inequalities.

468 Previous studies have shown that *DPYD* intermediate and poor metabolizers
469 receiving conventional doses of fluoropyrimidine are at significantly higher risk for severe
470 toxicity and treatment-related mortality ^{31,32} and pre-treatment testing followed by
471 genotype-guided dose reduction in variant carriers significantly reduces toxicity and
472 mortality risks ³¹⁻³⁵, and associated hospitalisations ^{32,96-98}. This strategy has also been
473 shown to be cost-effective. For example, a UK-based study of an extended *DPYD* genetic

474 panel showed that genotyping was dominant over standard of care, with a saving of £78,000
475 per patient over a lifetime ⁹⁹. Two other studies, one from Canada¹⁰⁰ and another from
476 Iran¹⁰¹, have also shown pre-prescription *DPYD* genotyping to be cost saving, while studies
477 from the US⁹⁶ and Spain¹⁰² showed it to be cost-effective.

478 Our systematic review has limitations. We had to rely on observational studies,
479 including case reports, to identify affected patients. Clearly this represents selective
480 reporting, and many patients with important variants are either not reported, or more likely
481 not genotyped or sequenced. It is therefore important to identify and sequence these patients
482 to evaluate the full spectrum of mutations associated with toxicity from 5-FU or its
483 analogues. For many of the variants identified, the functional consequences are unknown.
484 In this review, we have undertaken a comprehensive *in silico* evaluation of the likely
485 functional consequences of the mutations, but further functional evaluation will be needed
486 for many of the variants. Notably, our systematic review has identified a number of patients
487 carrying more than one *DPYD* variant and in particular one African-American carrying 2
488 loss-of-function variants c.295_298delTCAT and c.1898delC in addition to the decreased
489 function variant c.557A>G (Supplementary Results)⁶²; how the co-expression of functional
490 *DPYD* variants affects overall DPD activity and the consequences for the severity of
491 fluoropyrimidine-related toxicity remains to be elucidated. Our focus has been on the *DPYD*
492 gene, but there are other potential genes (e.g. *MIR27A*, *TYMS*, *ENOSF1*, *MHTFR*) which
493 may be important in predisposing to toxicity from the fluoropyrimidines, and these will need
494 a separate evaluation.

495 In conclusion, our systematic review has focused on non-European patients and has
496 identified numerous variants in the *DPYD* gene which have been reported in patients with
497 severe toxicity after treatment with 5-FU or its oral analogues. The UK is an increasingly
498 multi-cultural and ethnically diverse society but we test for 4 variants which have been
499 identified from studies undertaken in European populations. However, our analysis shows
500 that 3 of these 4 variants are also important in South Asian, East Asian and Middle Eastern
501 individuals. From the evidence gathered, and based on practice elsewhere in the world, we
502 feel that it would be important to extend *DPYD* genetic testing in the UK NHS to include
503 the c.557A>G variant which has been identified in individuals of African ancestry. The
504 other variants described in this systematic review need further evaluation for incorporation
505 into the testing pathways either in the UK or elsewhere, but of course, if sequencing
506 becomes the standard method for characterising *DPYD* variation, we hope the information
507 contained within this systematic review will be of use to diagnostic labs and policy makers.

508

509 **Additional Information**

510

511 **Authors' contributions**

512 Conceptualization, M.P. and E.J.Z.; Methodology, T.H.C. and E.J.Z.; Data review, T.H.C.
513 and E.J.Z.; *In silico* analysis, T.H.C.; Writing – Original Draft Preparation, T.H.C. and
514 E.J.Z.; Writing – Review and Editing, T.H.C., E.J.Z. and M.P.; Supervision, E.J.Z. and M.P.
515 All authors have read and agreed to the published version of the manuscript.

516

517 **Ethics approval and consent to participate**

518 Ethics approval was not required for this review.

519

520 **Data availability**

521 Data used in this review is provided in Supplementary Appendices; any additional data are
522 available upon request to the corresponding author.

523

524 **Competing interests**

525 MP has received partnership funding for the following: MRC Clinical Pharmacology
526 Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis). He has
527 developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially
528 from this. He is part of the IMI Consortium ARDAT (www.ardat.org). None of the funding
529 MP received is related to the current paper.

530 The remaining authors declare that the research was conducted in the absence of any
531 commercial or financial relationships that could be construed as a potential conflict of
532 interest.

533

534 **Funding information**

535 This work was supported by the NHS Race & Health Observatory.

536

537

538

539 **References**

- 540 1 Thorn, C. F. *et al.* PharmGKB summary: fluoropyrimidine pathways.
541 *Pharmacogenet Genomics* **21**, 237-242 (2011).
- 542 2 Lee, A. M. *et al.* DPYD variants as predictors of 5-fluorouracil toxicity in
543 adjuvant colon cancer treatment (NCCTG N0147). *J Natl Cancer Inst* **106**
544 (2014).
- 545 3 WHO. Model List of Essential Medicines—1st List, 1977.
546 <https://www.who.int/publications/i/item/9241206152> (1977).
- 547 4 WHO. Selection and Use of Essential Medicines: Report of the WHO Expert
548 Committee, 2015 (including the 19th WHO Model List of Essential Medicines
549 and the 5th WHO Model List of Essential Medicines for Children). **994**, 1-
550 546 (2015).
- 551 5 European Medicines Agency (EMA). Referral under Article 31 of Directive
552 2001/83/EC resulting from pharmacovigilance data: fluorouracil and
553 fluorouracil-related substances (capecitabine, tegafur and flucytosine)
554 containing medicinal products. Available at
555 [https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-](https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf)
556 [related-substances-article-31-referral-assessment-report_en.pdf](https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf) (2020).
- 557 6 Amstutz, U. *et al.* Clinical Pharmacogenetics Implementation Consortium
558 (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and
559 Fluoropyrimidine Dosing: 2017 Update. *Clin Pharmacol Ther* **103**, 210-216
560 (2018).
- 561 7 Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of
562 Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA*
563 *Cancer J Clin* **71**, 209-249 (2021).
- 564 8 Meta-Analysis Group In, C. *et al.* Toxicity of fluorouracil in patients with
565 advanced colorectal cancer: effect of administration schedule and prognostic
566 factors. *J Clin Oncol* **16**, 3537-3541 (1998).
- 567 9 Rosmarin, D. *et al.* Genetic markers of toxicity from capecitabine and other
568 fluorouracil-based regimens: investigation in the QUASAR2 study,
569 systematic review, and meta-analysis. *J Clin Oncol* **32**, 1031-1039 (2014).
- 570 10 Froehlich, T. K., Amstutz, U., Aebi, S., Joerger, M. & Largiader, C. R. Clinical
571 importance of risk variants in the dihydropyrimidine dehydrogenase gene for
572 the prediction of early-onset fluoropyrimidine toxicity. *Int J Cancer* **136**, 730-
573 739 (2015).
- 574 11 Meulendijks, D. *et al.* Clinical relevance of DPYD variants c.1679T>G,
575 c.1236G>A/HapB3, and c.1601G>A as predictors of severe
576 fluoropyrimidine-associated toxicity: a systematic review and meta-analysis
577 of individual patient data. *Lancet Oncol* **16**, 1639-1650 (2015).
- 578 12 Saltz, L. B. *et al.* Irinotecan plus fluorouracil and leucovorin for metastatic
579 colorectal cancer. Irinotecan Study Group. *N Engl J Med* **343**, 905-914
580 (2000).
- 581 13 Bajetta, E. *et al.* Safety and efficacy of two different doses of capecitabine in
582 the treatment of advanced breast cancer in older women. *J Clin Oncol* **23**,
583 2155-2161 (2005).
- 584 14 Tsalic, M., Bar-Sela, G., Beny, A., Visel, B. & Haim, N. Severe toxicity related
585 to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a
586 prospective study in colorectal cancer patients. *Am J Clin Oncol* **26**, 103-106
587 (2003).
- 588 15 Hoff, P. M. *et al.* Comparison of oral capecitabine versus intravenous
589 fluorouracil plus leucovorin as first-line treatment in 605 patients with

- 590 metastatic colorectal cancer: results of a randomized phase III study. *J Clin*
591 *Oncol* **19**, 2282-2292 (2001).
- 592 16 Van Cutsem, E. *et al.* Oral capecitabine compared with intravenous
593 fluorouracil plus leucovorin in patients with metastatic colorectal cancer:
594 results of a large phase III study. *J Clin Oncol* **19**, 4097-4106 (2001).
- 595 17 Tuchman, M. *et al.* Familial pyrimidinemia and pyrimidinuria associated with
596 severe fluorouracil toxicity. *N Engl J Med* **313**, 245-249 (1985).
- 597 18 Sommadossi, J. P. *et al.* Rapid Catabolism of 5-Fluorouracil in Freshly
598 Isolated Rat Hepatocytes as Analyzed by High-Performance Liquid-
599 Chromatography. *Journal of Biological Chemistry* **257**, 8171-8176 (1982).
- 600 19 Traut, T. W. & Loechel, S. Pyrimidine catabolism: individual characterization
601 of the three sequential enzymes with a new assay. *Biochemistry* **23**, 2533-
602 2539 (1984).
- 603 20 Diasio, R. B., Beavers, T. L. & Carpenter, J. T. Familial deficiency of
604 dihydropyrimidine dehydrogenase. Biochemical basis for familial
605 pyrimidinemia and severe 5-fluorouracil-induced toxicity. *J Clin Invest* **81**,
606 47-51 (1988).
- 607 21 Harris, B. E., Carpenter, J. T. & Diasio, R. B. Severe 5-fluorouracil toxicity
608 secondary to dihydropyrimidine dehydrogenase deficiency. A potentially
609 more common pharmacogenetic syndrome. *Cancer* **68**, 499-501 (1991).
- 610 22 Takimoto, C. H. *et al.* Severe neurotoxicity following 5-fluorouracil-based
611 chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
612 *Clin Cancer Res* **2**, 477-481 (1996).
- 613 23 van Kuilenburg, A. B. Dihydropyrimidine dehydrogenase and the efficacy
614 and toxicity of 5-fluorouracil. *Eur J Cancer* **40**, 939-950 (2004).
- 615 24 Lunenburg, C. *et al.* Dutch Pharmacogenetics Working Group (DPWG)
616 guideline for the gene-drug interaction of DPYD and fluoropyrimidines. *Eur*
617 *J Hum Genet* **28**, 508-517 (2020).
- 618 25 Morel, A. *et al.* Clinical relevance of different dihydropyrimidine
619 dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil
620 tolerance. *Mol Cancer Ther* **5**, 2895-2904 (2006).
- 621 26 van Kuilenburg, A. B., van Lenthe, H. & van Gennip, A. H. Activity of
622 pyrimidine degradation enzymes in normal tissues. *Nucleosides Nucleotides*
623 *Nucleic Acids* **25**, 1211-1214 (2006).
- 624 27 Van Kuilenburg, A. B., van Lenthe, H., Blom, M. J., Mul, E. P. & Van Gennip,
625 A. H. Profound variation in dihydropyrimidine dehydrogenase activity in
626 human blood cells: major implications for the detection of partly deficient
627 patients. *Br J Cancer* **79**, 620-626 (1999).
- 628 28 Johnson, M. R., Wang, K., Tillmanns, S., Albin, N. & Diasio, R. B. Structural
629 organization of the human dihydropyrimidine dehydrogenase gene. *Cancer*
630 *Res* **57**, 1660-1663 (1997).
- 631 29 Wei, X. *et al.* Characterization of the human dihydropyrimidine
632 dehydrogenase gene. *Genomics* **51**, 391-400 (1998).
- 633 30 Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from
634 variation in 141,456 humans. *Nature* **581**, 434-443 (2020).
- 635 31 Henricks, L. M. *et al.* DPYD genotype-guided dose individualisation of
636 fluoropyrimidine therapy in patients with cancer: a prospective safety
637 analysis. *Lancet Oncol* **19**, 1459-1467 (2018).
- 638 32 Deenen, M. J. *et al.* Upfront Genotyping of DPYD*2A to Individualize
639 Fluoropyrimidine Therapy: A Safety and Cost Analysis. *J Clin Oncol* **34**, 227-
640 234 (2016).

- 641 33 Henricks, L. M. *et al.* Effectiveness and safety of reduced-dose
642 fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A
643 matched pair analysis. *Int J Cancer* **144**, 2347-2354 (2019).
- 644 34 Glewis, S. *et al.* A systematic review and meta-analysis of toxicity and
645 treatment outcomes with pharmacogenetic-guided dosing compared to
646 standard of care BSA-based fluoropyrimidine dosing. *Br J Cancer* **127**, 126-
647 136 (2022).
- 648 35 Wigle, T. J. *et al.* Impact of pretreatment dihydropyrimidine dehydrogenase
649 genotype-guided fluoropyrimidine dosing on chemotherapy associated
650 adverse events. *Clin Transl Sci* **14**, 1338-1348 (2021).
- 651 36 European Medicines Agency (EMA). 5-Fluorouracil (i.v.), capecitabine and
652 tegafur containing products: Pre-treatment testing to identify DPD-deficient
653 patients at increased risk of severe toxicity. Available at
654 [https://www.ema.europa.eu/en/medicines/dhpc/5-fluorouracil-iv-
655 capecitabine-tegafur-containing-products-pre-treatment-testing-identify-
656 dpd#documents-section](https://www.ema.europa.eu/en/medicines/dhpc/5-fluorouracil-iv-capecitabine-tegafur-containing-products-pre-treatment-testing-identify-dpd#documents-section) (2020).
- 657 37 NHS England. Clinical Commissioning Urgent Policy Statement:
658 Pharmacogenomic Testing for DPYD Polymorphisms with Fluoropyrimidine
659 Therapies. Available at [https://www.england.nhs.uk/publication/clinical-
660 commissioning-urgent-policy-statement-pharmacogenomic-testing-for-
661 dpyd-polymorphisms-with-fluoropyrimidine-therapies/](https://www.england.nhs.uk/publication/clinical-commissioning-urgent-policy-statement-pharmacogenomic-testing-for-dpyd-polymorphisms-with-fluoropyrimidine-therapies/) (2020).
- 662 38 Vreken, P. *et al.* A point mutation in an invariant splice donor site leads to
663 exon skipping in two unrelated Dutch patients with dihydropyrimidine
664 dehydrogenase deficiency. *J Inherit Metab Dis* **19**, 645-654 (1996).
- 665 39 Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J. & Fernandez-
666 Salguero, P. Molecular basis of the human dihydropyrimidine
667 dehydrogenase deficiency and 5-fluorouracil toxicity. *J Clin Invest* **98**, 610-
668 615 (1996).
- 669 40 Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**,
670 68-74 (2015).
- 671 41 Chen, S. *et al.* A genome-wide mutational constraint map quantified from
672 variation in 76,156 human genomes. In: 10.1101/2022.03.20.485034
673 (bioRxiv, 2022).
- 674 42 Elraiyah, T. *et al.* Novel Deleterious Dihydropyrimidine Dehydrogenase
675 Variants May Contribute to 5-Fluorouracil Sensitivity in an East African
676 Population. *Clin Pharmacol Ther* **101**, 382-390 (2017).
- 677 43 Afolabi, B. L. *et al.* Pharmacogenetics and Adverse Events in the Use of
678 Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care
679 Treatment in Zimbabwe. *J Pers Med* **13** (2023).
- 680 44 He, Y. F. *et al.* Analysis of the DPYD gene implicated in 5-fluorouracil
681 catabolism in Chinese cancer patients. *J Clin Pharm Ther* **33**, 307-314
682 (2008).
- 683 45 Hishinuma, E. *et al.* Functional Characterization of 21 Allelic Variants of
684 Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.
685 *Drug Metab Dispos* **46**, 1083-1090 (2018).
- 686 46 Kanai, M. *et al.* Poor association between dihydropyrimidine dehydrogenase
687 (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian
688 population. *Cancer Med* **12**, 7808-7814 (2023).
- 689 47 Maekawa, K. *et al.* Genetic variations and haplotype structures of the DPYD
690 gene encoding dihydropyrimidine dehydrogenase in Japanese and their
691 ethnic differences. *J Hum Genet* **52**, 804-819 (2007).

- 692 48 Yokoi, K. *et al.* Impact of DPYD, DPYS, and UPB1 gene variations on severe
693 drug-related toxicity in patients with cancer. *Cancer Sci* **111**, 3359-3366
694 (2020).
- 695 49 White, C. *et al.* Ethnic Diversity of DPD Activity and the DPYD Gene: Review
696 of the Literature. *Pharmacogenomics Pers Med* **14**, 1603-1617 (2021).
- 697 50 Page, M. J. *et al.* PRISMA 2020 explanation and elaboration: updated
698 guidance and exemplars for reporting systematic reviews. *BMJ* **372**, n160
699 (2021).
- 700 51 Common Terminology Criteria for Adverse Events (CTCAE). National
701 Cancer Institute (NCI), National Institutes of Health (NIH), US Department of
702 Health and Human Services. Available at
703 [https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.ht](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm)
704 [m](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm).
- 705 52 WHO Handbook for reporting results of Cancer Treatment. WHO offset
706 publication No. 48. Available at
707 <https://apps.who.int/iris/handle/10665/37200>. Geneva (1979).
- 708 53 Shrestha, S. *et al.* Gene-Specific Variant Classifier (DPYD-Varifier) to
709 Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. *Clin*
710 *Pharmacol Ther* **104**, 709-718 (2018).
- 711 54 Zhou, Y., Dagli Hernandez, C. & Lauschke, V. M. Population-scale
712 predictions of DPD and TPMT phenotypes using a quantitative
713 pharmacogene-specific ensemble classifier. *Br J Cancer* **123**, 1782-1789
714 (2020).
- 715 55 Zhou, Y., Mkrtchian, S., Kumondai, M., Hiratsuka, M. & Lauschke, V. M. An
716 optimized prediction framework to assess the functional impact of
717 pharmacogenetic variants. *Pharmacogenomics J* **19**, 115-126 (2019).
- 718 56 Offer, S. M., Wegner, N. J., Fossum, C., Wang, K. & Diasio, R. B. Phenotypic
719 profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-
720 time cellular analysis and in vitro measurement of enzyme activity. *Cancer*
721 *Res* **73**, 1958-1968 (2013).
- 722 57 Offer, S. M. *et al.* Comparative functional analysis of DPYD variants of
723 potential clinical relevance to dihydropyrimidine dehydrogenase activity.
724 *Cancer Res* **74**, 2545-2554 (2014).
- 725 58 Kuilenburg, A. *et al.* Phenotypic and clinical implications of variants in the
726 dihydropyrimidine dehydrogenase gene. *Biochim Biophys Acta* **1862**, 754-
727 762 (2016).
- 728 59 Hishinuma, E. *et al.* Importance of Rare DPYD Genetic Polymorphisms for
729 5-Fluorouracil Therapy in the Japanese Population. *Front Pharmacol* **13**,
730 930470 (2022).
- 731 60 Leung, M., Rogers, J. E. & Shureiqi, I. Use of Uridine Triacetate to Reverse
732 Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a
733 Patient With a c.557A>G Heterozygous DPYD Variant. *Clin Colorectal*
734 *Cancer* **20**, 273-278 (2021).
- 735 61 Saif, M. W. *et al.* A DPYD variant (Y186C) specific to individuals of African
736 descent in a patient with life-threatening 5-FU toxic effects: potential for an
737 individualized medicine approach. *Mayo Clin Proc* **89**, 131-136 (2014).
- 738 62 Sissung, T. M. *et al.* Case report: severe toxicity in an African-American
739 patient receiving FOLFOX carrying uncommon allelic variants in DPYD.
740 *Pharmacogenomics* **22**, 81-85 (2021).
- 741 63 Maharjan, A. S. *et al.* The Prevalence of DPYD*9A(c.85T>C) Genotype and
742 the Genotype-Phenotype Correlation in Patients with Gastrointestinal

- 743 Malignancies Treated With Fluoropyrimidines: Updated Analysis. *Clin*
744 *Colorectal Cancer* **18**, e280-e286 (2019).
- 745 64 Wasif Saif, M. M. D. a. *et al.* A DPYD Variant (Y186C) Specific to Individuals
746 of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects:
747 Potential for an Individualized Medicine Approach. *Mayo Clinic Proceedings*
748 **89**, 131-136 (2014).
- 749 65 Hishinuma, E., Gutierrez Rico, E. & Hiratsuka, M. In Vitro Assessment of
750 Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine
751 Dehydrogenase, Dihydropyrimidinase, and beta-Ureidopropionase. *J Clin*
752 *Med* **9** (2020).
- 753 66 Deng, X., Hou, J., Deng, Q. & Zhong, Z. Predictive value of clinical toxicities
754 of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer
755 by DPYD and GSTP1 gene polymorphisms. *World J Surg Oncol* **18**, 321
756 (2020).
- 757 67 Liu, D. *et al.* Examination of multiple UGT1A and DPYD polymorphisms has
758 limited ability to predict the toxicity and efficacy of metastatic colorectal
759 cancer treated with irinotecan-based chemotherapy: a retrospective
760 analysis. *BMC Cancer* **17**, 437 (2017).
- 761 68 Nie, Q. H. *et al.* Effects of DPYD and TS gene polymorphisms on
762 chemosensitivity of 5-FU in advanced colorectal cancer. *International*
763 *Journal of Clinical and Experimental Medicine* **12**, 9380-9386 (2019).
- 764 69 Sun, W., Yan, C., Jia, S. & Hu, J. Correlation analysis of peripheral DPYD
765 gene polymorphism with 5-fluorouracil susceptibility and side effects in colon
766 cancer patients. *Int J Clin Exp Med* **7**, 5857-5861 (2014).
- 767 70 Zhang, X., Sun, B. & Lu, Z. Evaluation of clinical value of single nucleotide
768 polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-
769 fluorouracil toxicity in 60 colorectal cancer patients in China. *Int J Med Sci*
770 **10**, 894-902 (2013).
- 771 71 Shao, T. *et al.* Capecitabine-induced enterocolitis: a case report and
772 pharmacogenetic profile. *Pharmacogenomics* **23**, 953-959 (2022).
- 773 72 Tong, C. C., Lam, C. W., Lam, K. O., Lee, V. H. F. & Luk, M. Y. A Novel
774 DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role
775 of Pre-emptive DPYD Genotype Screening. *Front Oncol* **8**, 279 (2018).
- 776 73 Ishiguro, M. *et al.* A Japanese Patient with Gastric Cancer and
777 Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD
778 Variants. *Acta Med Okayama* **74**, 557-562 (2020).
- 779 74 Kouwaki, M. *et al.* Identification of novel mutations in the dihydropyrimidine
780 dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. *Clin*
781 *Cancer Res* **4**, 2999-3004 (1998).
- 782 75 Yoshida, Y. *et al.* 5-Fluorouracil Chemotherapy for Dihydropyrimidine
783 Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method.
784 *Anticancer Res* **35**, 4881-4887 (2015).
- 785 76 Cho, H. J., Park, Y. S., Kang, W. K., Kim, J. W. & Lee, S. Y. Thymidylate
786 synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD)
787 polymorphisms in the Korean population for prediction of 5-fluorouracil-
788 associated toxicity. *Ther Drug Monit* **29**, 190-196 (2007).
- 789 77 Sirachainan, E. Pharmacogenetic Study of 5-Fluorouracil-Related Severe
790 Toxicity in Thai Cancer Patients: A Novel SNP Detection. *Journal of*
791 *Pharmacogenomics & Pharmacoproteomics* **03** (2012).
- 792 78 Cordova-Delgado, M. *et al.* A case-control study of a combination of single
793 nucleotide polymorphisms and clinical parameters to predict clinically

- 794 relevant toxicity associated with fluoropyrimidine and platinum-based
795 chemotherapy in gastric cancer. *BMC Cancer* **21**, 1030 (2021).
- 796 79 Ben Fredj, R., Gross, E., Ben Ahmed, S., Hassine, H. & Saguem, S. The
797 dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for
798 screening of dihydropyrimidine dehydrogenase deficiency in colorectal
799 cancer patients treated with 5-fluorouracil. *Pathol Biol (Paris)* **57**, 470-476
800 (2009).
- 801 80 Khalij, Y. *et al.* DPYD and TYMS polymorphisms as predictors of 5
802 fluorouracil toxicity in colorectal cancer patients. *J Chemother* **35**, 425-434
803 (2022).
- 804 81 Almashagbah, N. A., Mahasneh, A. A. & Bodoor, K. G. Pharmacogenetic
805 Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients
806 with Colorectal Cancer. *Asian Pac J Cancer Prev* **23**, 3061-3069 (2022).
- 807 82 Mukherji, D., Massih, S. A., Tfayli, A., Kanso, M. & Faraj, W. Three different
808 polymorphisms of the DPYD gene associated with severe toxicity following
809 administration of 5-FU: a case report. *J Med Case Rep* **13**, 76 (2019).
- 810 83 Bukhari, N. *et al.* Fluoropyrimidine-Induced Severe Toxicities Associated
811 with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a
812 Review of the Literature. *Clin Pract* **11**, 467-471 (2021).
- 813 84 Dhawan, D., Panchal, H., Shukla, S. & Padh, H. Genetic variability &
814 chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a
815 preliminary study. *Indian J Med Res* **137**, 125-129 (2013).
- 816 85 Hariprakash, J. M. *et al.* Pharmacogenetic landscape of DPYD variants in
817 south Asian populations by integration of genome-scale data.
818 *Pharmacogenomics* **19**, 227-241 (2018).
- 819 86 Patil, V. M. *et al.* Dihydropyrimidine dehydrogenase mutation in neoadjuvant
820 chemotherapy in head and neck cancers: Myth or reality? *South Asian J*
821 *Cancer* **5**, 182-185 (2016).
- 822 87 Sahu, A., Ramaswamy, A. & Ostwal, V. Dihydro pyrimidine dehydrogenase
823 deficiency in patients treated with capecitabine based regimens: a tertiary
824 care centre experience. *J Gastrointest Oncol* **7**, 380-386 (2016).
- 825 88 Vinin, N. V., Jones, J. & Geetha, M. Clinical Suspicion & Dpd/Dypd Mutation
826 Positivity In Patients Receiving Chemotherapy With Capecitabine / 5
827 Fluorouracil (5 Fu). *Journal of Cancer Research & Therapeutics* **13**, S218-
828 S218 (2017).
- 829 89 Rastogi, S., Sirohi, B., Deodhar, K., Shetty, N. & Shrikhande, S. V. Dilemma
830 of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients:
831 is Uftoral(R) the right answer? *Colorectal Cancer* **3**, 315-319 (2014).
- 832 90 Ly, R. C. *et al.* Severe Capecitabine Toxicity Associated With a Rare DPYD
833 Variant Identified Through Whole-Genome Sequencing. *JCO Precis Oncol*
834 **4**, 632-638 (2020).
- 835 91 Nahid, N. A. *et al.* DPYD*2A and MTHFR C677T predict toxicity and efficacy,
836 respectively, in patients on chemotherapy with 5-fluorouracil for colorectal
837 cancer. *Cancer Chemother Pharmacol* **81**, 119-129 (2018).
- 838 92 Office for National Statistics. Ethnic group, England and Wales: Census
839 2021. Available at
840 [https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/eth](https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/bulletins/ethnicgroupenglandandwales/census2021)
841 [nicity/bulletins/ethnicgroupenglandandwales/census2021](https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/bulletins/ethnicgroupenglandandwales/census2021) (2021).
- 842 93 Morel, A., Boisdron-Celle, M., Fey, L., Laine-Cessac, P. & Gamelin, E.
843 Identification of a novel mutation in the dihydropyrimidine dehydrogenase
844 gene in a patient with a lethal outcome following 5-fluorouracil administration

- 845 and the determination of its frequency in a population of 500 patients with
846 colorectal carcinoma. *Clin Biochem* **40**, 11-17 (2007).
- 847 94 Zaanan, A., Dumont, L. M., Lorient, M. A., Taieb, J. & Narjoz, C. A case of 5-
848 FU-related severe toxicity associated with the p.Y186C DPYD variant. *Clin*
849 *Pharmacol Ther* **95**, 136 (2014).
- 850 95 Offer, S. M. *et al.* A DPYD variant (Y186C) in individuals of african ancestry
851 is associated with reduced DPD enzyme activity. *Clin Pharmacol Ther* **94**,
852 158-166 (2013).
- 853 96 Brooks, G. A., Tapp, S., Daly, A. T., Busam, J. A. & Tosteson, A. N. A. Cost-
854 effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant
855 Chemotherapy for Colon Cancer. *Clin Colorectal Cancer* **21**, e189-e195
856 (2022).
- 857 97 Morris, S. A. *et al.* Cost Effectiveness of Pharmacogenetic Testing for Drugs
858 with Clinical Pharmacogenetics Implementation Consortium (CPIC)
859 Guidelines: A Systematic Review. *Clin Pharmacol Ther* **112**, 1318-1328
860 (2022).
- 861 98 Rivers, Z. *et al.* A cost-effectiveness analysis of pretreatment DPYD and
862 UGT1A1 screening in patients with metastatic colorectal cancer (mCRC)
863 treated with FOLFIRI plus bevacizumab (FOLFIRI plus Bev). *Journal of*
864 *Clinical Oncology* **38**, 168 (2020).
- 865 99 Koleva-Kolarova, R. *et al.* Budget impact and transferability of cost-
866 effectiveness of DPYD testing in metastatic breast cancer in three health
867 systems. *Per Med* **20**, 357-374 (2023).
- 868 100 Ontario, H. DPYD Genotyping in Patients Who Have Planned Cancer
869 Treatment With Fluoropyrimidines: A Health Technology Assessment. *Ont*
870 *Health Technol Assess Ser* **21**, 1-186 (2021).
- 871 101 Fariman, S. A., Jahangard Rafsanjani, Z., Hasanzad, M., Niksalehi, K. &
872 Nikfar, S. Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-
873 Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A
874 Cost-Effectiveness Analysis. *Value Health Reg Issues* **37**, 71-80 (2023).
- 875 102 Cortejoso, L. *et al.* Cost-effectiveness of screening for DPYD polymorphisms
876 to prevent neutropenia in cancer patients treated with fluoropyrimidines.
877 *Pharmacogenomics* **17**, 979-984 (2016).

878
879
880
881
882
883
884
885
886
887
888
889
890
891

892 **Figure Legends**

893

894 **Figure 1: PRISMA flow diagram of study selection.** Our search of four electronic databases
895 identified a total of 10310 records, 447 from MEDLINE (PubMed), 1355 from Web of Science,
896 3192 from Embase (OVID), 5316 from Scopus. After removing 2178 duplicates, 8132 unique
897 records remained which included 18 conference abstracts and 3 non-English articles. Following the
898 title and abstract screening phase, 8052 records that did not meet the inclusion criteria were
899 excluded. Full-text inspection of the remaining 80 articles identified 31 articles that met the
900 eligibility criteria for inclusion. Screening the reference lists of these 31 articles identified one more
901 relevant article, and so 32 articles were finally included in the present systematic review.

902

903 **Figure 2: 53 *DPYD* variants identified in our systematic review.** Variants listed in the CPIC
904 guideline are highlighted in blue. The four prominent European *DPYD* variants are in bold blue font.
905 ^ac.2846A>T was not identified in our systematic review.

906

Table 1. Characteristics of included studies.

Authors, year	Study design	Ethnic population, Ethnic origin, Country	Severe toxicity patients / Total patients (n)	Gender	Age/ Age range (years)	Cancer type	Chemotherapy regimen ^{abc}	Severe toxicity grading tool	Grade 3-4 toxicity manifestations	DPYD variants identified	DPYD genetic testing method	FP dose modification/ discontinuation
Kouwaki et al, 1998	Case study	East Asia, Japanese, Japan	1/1	Female	57	Breast cancer	5-FU-based	WHO	Leukopenia, Thrombocytopenia, Mucositis	c.62G>A, Arg21Gln c.1003G>T, Val335Leu, *11 c.1156G>T, Glu386Ter, *12 c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.1129-15T>C c.1525-9A>G c.1627A>G, Ile543Val, *5 c.1737T>C, Asp579Asp c.1740+39C>T c.1774C>T, Arg592Trp c.1896T>C, Phe632=	PCR-RFLP of exons 2 & 11, Sanger sequencing of exon 10	Yes
Cho et al, 2007	Cohort retrospective	East Asia, Korean, Korea	21/21	43% Male	31 - 71	Colorectal cancer	5-FU-based	CTCAE version 2.0	Neutropenia, Stomatitis, Fatigue, Diarrhoea, Vomiting, Nausea, Fatigue	c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.1129-15T>C c.1525-9A>G c.1627A>G, Ile543Val, *5 c.1737T>C, Asp579Asp c.1740+39C>T c.1774C>T, Arg592Trp c.1896T>C, Phe632= c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.1129-15T>C c.1601G>A, Ser534Asn, *4 c.1627A>G, Ile543Val, *5	Sanger sequencing of exons & flanking introns	No
Ben Fredj et al, 2009	Cohort prospective	Middle East, Tunisian, Tunisia	1/9	33% Male	25 - 79	Advanced colorectal cancer	5-FU-based	Unreported, used term 'grade 3'	Alopecia	c.967G>A, Ala323Thr c.1236G>A, Glu412= c.1627A>G, Ile543Val, *5 c.1774C>T, Arg592Trp c.1896T>C, Phe632= c.1905+1G>A, *2A	DHPLC & Sanger sequencing	No
Sirachainan et al, 2012	Cohort retrospective	East Asia, Thai, Thailand	76/76	U/R	U/R	52% Breast cancer, 35% Gastrointestinal tract cancer, 12% Head and Neck cancer, 1% Squamous cell cancer	5-FU-based	Unreported, used term 'grade ≥3'	Neutropenia	c.967G>A, Ala323Thr c.1236G>A, Glu412= c.1627A>G, Ile543Val, *5 c.1774C>T, Arg592Trp c.1896T>C, Phe632= c.1905+1G>A, *2A	Sanger sequencing of exons 1, 8, 10, 11, 13, 14 & 17	No
Dhawan et al, 2013	Cohort prospective	South Asia, Indian, India	2/23	Male	U/R	Head and Neck cancer	5-FU-based	CTCAE version 3.0	Not specified, referred to as grade 4 toxicity	c.85T>C, Cys29Arg, *9A c.1905+1G>A, *2A	Allele-specific multiplex PCR and long-range PCR of selected variants c.85T>C, c.1905+1G>A, c.2194G>A, c.2846A>T	No
Zhang et al, 2013	Cohort prospective	East Asia, Chinese, China	14/60	57% Male	40 - 68	Colorectal cancer	5-FU-based	WHO	Bone marrow toxicity, Gastrointestinal toxicity	c.85T>C, Cys29Arg, *9A c.464T>A, Leu155Ter c.2194G>A, Val732Ile, *6	TaqMan genotyping of 5 selected variants c.85T>C, c.464T>A, c.1156G>T, c.1905+1G>A, c.2194G>A	No
Rastogi et al, 2014	Case series	South Asia, Indian, India	3/3	66% Male	44 - 65	Colon cancer	Combination of Capecitabine-based and Tegafur-based	Unreported, used term 'grade ≥3'	Neutropenia, Diarrhoea, Thrombocytopenia, Febrile neutropenia, Mucositis, Hand-Foot-Syndrome	c.496A>G, Met166Val c.1627A>G, Ile543Val, *5 c.1905+1G>A, *2A	Candidate genotyping	Yes
Saif et al, 2014	Case study	African American, African American, USA	1/1	Female	60	Colon cancer	5-FU-based	Unreported, used term 'severe'	Pancytopenia, Mucositis	1:n.688+20094C>T c.85T>C, Cys29Arg, *9A c.557A>G, Tyr186Cys c.680+139G>A c.681-29G>T c.763-118A>G c.1906-123C>A c.1974+75T>C c.2766+371>C c.2908-69A>G c.*768G>A	Sanger sequencing of all 23 exons in DPYD	No
Sun et al, 2014	Cohort prospective	East Asia, Chinese, China	14/100	57% Male	31 - 71	Colon cancer	5-FU-based	WHO	Myelosuppression, Diarrhoea, Mucositis, Gastrointestinal toxicity, Hand-Foot syndrome	c.85T>C, Cys29Arg, *9A c.1627A>G, Ile543Val, *5 c.1905+1G>A, *2A	High resolution melting of selected variants c.85T>C, c.1627A>G, c.1905+1G>A	No
Yoshida et al, 2015	Case study	East Asia, Japanese, Japan	1/1	Male	73	Intestinal cancer	5-FU-based	Unreported, used term 'grade 4'	Leukopenia, Neutropenia, Thrombocytopenia	c.1156G>T, Glu386Ter, *12	Sanger sequencing of all 23 exons in DPYD	Yes
Patil et al, 2016	Cohort prospective	South Asia, Indian, India	9/34	80% Male	21 - 59	Advanced Head and Neck cancer	5-FU-based	Unreported, used term 'grade ≥3'	Diarrhoea, Mucositis	c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.1601G>A, Ser534Asn, *4	PCR & sequencing of 11 selected variants including c.85T>C, c.496A>G, c.1601G>A, c.1627A>G,	Yes

										c.1627A>G, Ile543Val, *5 c.2194G>A, Val732Ile, *6	c.1905+1G>A, c.2194G>A, c.2846A>T	
Sahu et al, 2016	Cohort prospective	South Asia, Indian, India	31/31	71% Male	26 - 67	70% Colorectal cancer, 29% Stomach cancer, 1% Gallbladder cancer	Capecitabine-based	CTCAE (unknown version)	Myelosuppression, Diarrhoea, Mucositis, Hand-Foot syndrome	c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.1627A>G, Ile543Val, *5 c.1905+1G>A, *2A c.2194G>A, Val732Ile, *6	PCR & sequencing of 11 selected variants including c.85T>C, c.496A>G, c.1601G>A, c.1627A>G, c.1905+1G>A, c.2194G>A, c.2846A>T	Yes
Liu et al, 2017	Cohort retrospective	East Asia, Chinese, China	~75/~139	61% Male	47 - 63	Metastatic colorectal cancer	5-FU, Capecitabine or Tegafur-based (number unreported)	CTCAE version 4.0	Neutropenia, Diarrhoea	c.1627A>G, Ile543Val, *5 c.1896T>C, Phe632=	Sanger sequencing of selected variants c.1627A>G, c.1896T>C, c.1905+1G>A	No
Hariprakas et al, 2018	Cohort retrospective	South Asia, Indian, India	17/77	68% Male	15 - 82	70% Colorectal cancer, 8% Stomach cancer, 6% Oesophageal cancer, 6% Gastrointestinal cancer, 10% other cancer	Capecitabine-based	Unreported, used term 'grade ≥3'	Diarrhoea, Hand-Foot syndrome	c.496A>G, Met166Val c.1905+1G>A, *2A	Sanger sequencing of 15 selected variants including c.496A>G, c.557A>G (absent), c.1905+1G>A, c.1679T>G, c.2846A>T	No
Nahid et al, 2018	Cohort prospective	South Asia, Bangladeshi, Bangladesh	78/161	60% Male	25 - 75	Colorectal cancer	5-FU-based	CTCAE version 3.0	Anaemia, Leukopenia, Neutropenia, Diarrhoea, Thrombocytopenia, Mucositis, Vomiting, Nausea, Dermatological toxicity	c.1905+1G>A, *2A	PCR-RFLP of c.1905+1G>A	No
Tong et al, 2018	Case study	East Asia, Chinese, Hong Kong	1/1	Female	49	Sigmoid colon carcinoma	Capecitabine-based and 5-FU-based	CTCAE version 4.0	Bone marrow toxicity, Diarrhoea	c.321+2T>C	Sanger sequencing of all 23 exons in <i>DPYD</i>	Yes
Vinin et al, 2018	Cohort retrospective	South Asia, Indian, India	16/24	65% Male	24 - 77	73% Colorectal cancer, 17% Stomach cancer, 7% Breast cancer, 3% Tongue cancer	54% Capecitabine-based, 46% 5-FU-based	Unreported, used term 'grade ≥3'	Diarrhoea, Haematological toxicity, Hand-Foot syndrome, Mucositis, Electrolyte imbalance, Fatigue	c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.1627A>G, Ile543Val, *5 c.1905+1G>A, *2A c.2194G>A, Val732Ile, *6	PCR & sequencing - region/variant unspecified	No
Maharjan et al, 2019	Cohort retrospective	Caucasian, African American, Asian, Hispanic, Native American American, USA	~9 ^d /26	~55% Male	21 - 90	GI malignancies	5-FU-based	CTCAE version 5.0	Neutropenia, Diarrhoea, Mucositis, Vomiting/Nausea, Skin toxicity, Neurotoxicity	c.85T>C, Cys29Arg, *9A	Candidate genotyping of 5 selected variants c.-1590T>C, c.85T>C, c.1679T>G, c.1905+1G>A, c.2846A>T	No
Mukherji et al, 2019	Case study	Middle East, Lebanese, Lebanon	1/1	Female	59	Metastatic pancreatic cancer	5-FU-based	Unreported, used term 'grade 4'	Mucositis	c.1601G>A, Ser534Asn, *4 c.1905+1G>A, *2A c.2194G>A, Val732Ile, *6	NGS of exons and highly conserved intron-exon splice junctions	Yes
Nie et al, 2019	Cohort prospective	East Asia, Chinese, China	14/100	56% Male	51 - 77	Advanced colorectal cancer	5-FU-based	WHO	Myelosuppression, Mucosal damage, Gastrointestinal toxicity, Liver function damage	c.85T>C, Cys29Arg, *9A c.1627A>G, Ile543Val, *5	Sanger sequencing of selected variants c.85T>C, c.1627A>G	No
Deng et al, 2020	Cohort retrospective	East Asia, Chinese, China	~72/104	46% Male	25 - 78	Colorectal cancer	5-FU, Capecitabine or Oxaliplatin-based (number unreported)	CTCAE version 3.0	Anaemia, Leukopenia, Neutropenia, Diarrhoea, Thrombocytopenia, Mucositis, Vomiting, Hand-Foot syndrome, Skin ulceration	c.85T>C, Cys29Arg, *9A c.1627A>G, Ile543Val, *5	Sanger sequencing of selected variants c.85T>C, c.1627A>G, c.1905+1G>A	No
Ishiguro et al, 2020	Case study	East Asia, Japanese, Japan	1/1	Male	63	Stomach cancer	Capecitabine-based	CTCAE version 4.0	Neutropenia, Diarrhoea, Mucositis, Renal dysfunction	c.1615G>C, Gly539Arg c.1627A>G, Ile543Val, *5 c.1740+40A>G c.1740+39C>T c.1896T>C, Phe632= c.1974+75T>C IVS22+585C>T IVS23-69A>G	Sanger sequencing of all 23 exons in <i>DPYD</i>	Yes
Ly et al, 2020	Case study	South Asia, Indian, USA	1/1	Female	59	Metastatic colon cancer	Capecitabine-based and 5-FU-based	Unreported, used term 'grade 4'	Mucositis	c.704G>A, Arg235Gln	Candidate genotyping & whole genome sequencing	Yes
Yokoi et al, 2020	Cohort retrospective	East Asia, Japanese, Japan	55/301	44% Male	22 - 81	69% Colorectal cancer, 20% Stomach cancer,	5-FU-based	CTCAE version 4.0	Neutropenia, Diarrhoea, Vomiting, Nausea, Oral mucositis	c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.596G>A, Ser199Asn	NGS of exons and flanking introns	No

11% other cancer

c.733A>G, Ile245Val
c.1156G>T, Glu386Ter, *12
c.1627A>G, Ile543Val, *5
c.1712C>A, Ala571Asp
c.1863G>T, Trp621Cys
c.2194G>A, Val732Ile, *6
c.2303C>A, Thr768Lys
c.257C>T, Pro86Leu
c.1601G>A, Ser534Asn, *4
c.2434G>A, Val812Ile

Bukhari et al, 2021	Case series	Middle East, Saudi Arabian, Saudi Arabia	3/3	33% Male	64 - 66	Advanced distal rectal cancer	33% Capecitabine-based, 66% 5-FU-based	CTCAE (unknown version)	Diarrhoea, Fatigue, Mucositis, Pancytopenia	c.257C>T, Pro86Leu c.1601G>A, Ser534Asn, *4 c.2434G>A, Val812Ile	NGS of exons and eight selected intron-exon boundaries	Yes
Cordova-Delgado et al, 2021	Cohort retrospective	Latin American, Chilean, Chile	32/93	59% Male	28 - 77	Gastric cancer	10% Capecitabine-based, 90% 5-FU-based	CTCAE version 4.0	Anaemia, Neutropenia, Febrile Neutropenia, Diarrhoea, Vomiting, Nausea, Hand-Foot syndrome, Stomatitis, Peripheral neuropathy	c.85T>C, Cys29Arg, *9A c.496A>G, Met166Val c.1627A>G, Ile543Val, *5	TaqMan genotyping of 5 selected variants c.85T>C, c.496A>G, c.1627A>G	No
Leung et al, 2021	Case study	African American, African American, USA	1/1	Female	52	Splenic Flexure Colon cancer	5-FU-based	Unreported, used term 'grade 4'	Neutropenia	c.557A>G, Tyr186Cys	Sequencing of exons and intron-exon boundaries	Yes
Sissung et al, 2021	Case study	African American, African American, USA	1/1	Female	63	Metastatic colon cancer	5-FU-based	Unreported, used term 'severe'	Pancytopenia	c.40-3123T>A c.85T>C, Cys29Arg, *9A c.295_298delTCAT, Phe100fs, *7 c.557A>G, Tyr186Cys c.851-18271A>G c.1340-11501T>C c.1898delC, Pro633fs, *3 c.1906-28506C>G c.*5132C>T c.*21528C>T	DMET Plus & Pharmacoscan arrays	Yes
Almashagbah et al, 2022	Cohort prospective	Middle East, Jordanian, Jordan	44/80	53% Male	U/R	Colorectal cancer	5-FU-based	Dose-limiting toxicity	Neutropenia, Thrombocytopenia, Haemorrhage, Thrombosis, Diarrhoea, Neurotoxicity, Proteinuria, Hypertension	c.85T>C, Cys29Arg, *9A g.97515583_97515584insA c.1740+40A>G c.1740+39C>T	Sanger sequencing of exons 2, 4, 13, 22, intron 13 and exon-intron boundaries	No
Kanai et al, 2022	Cohort retrospective	East Asia, Japanese, Japan	~64/~495	U/R	U/R	Colon cancer	Capecitabine or 5-FU-based (unknown number)	CTCAE version 3.0 and 4.0	Neutropenia, Diarrhoea, Mucositis, Hand-Foot syndrome	c.85T>C, Cys29Arg, *9A c.451A>G, Asn151Asp c.496A>G, Met166Val c.1003G>T, Val335Leu, *11 c.1627A>G, Ile543Val, *5 c.2194G>A, Val732Ile, *6 c.2303C>A, Thr768Lys	Genome-wide genotyping	No
Khalij et al, 2022	Cohort prospective	Middle East, Tunisian, Tunisia	~2/~17	U/R	U/R	Colorectal cancer	5-FU-based	CTCAE version 3.0	Mucositis, Neurotoxicity	c.85T>C, Cys29Arg, *9A c.1679T>G, Ile560Ser, *13	PCR-RFLP of selected variants c.85T>C, c.496A>G, c.1679T>G, c.1905+1G>A, c.483+18G>A (HapB3)	No
Shao et al, 2022	Case study	East Asia, Chinese, China	1/1	Male	68	Rectal cancer	Capecitabine-based	CTCAE version 5.0	Diarrhoea	c.85T>C, Cys29Arg, *9A c.1627A>G, Ile543Val, *5	Whole exome sequencing	Yes

5-FU: 5-fluorouracil; CTCAE: Common Terminology Criteria for Adverse Events; FP: Fluoropyrimidine; GI: gastrointestinal; U/R: unreported; WHO: World Health Organisation.

^a 5-FU-based regimens include FOLFOX / mFOLFOX6 / FOLFOX4: 5-FU + oxaliplatin + leucovorin, FOLFOXIRIα: 5-FU + irinotecan + anti-VEGF/anti-EGFR antibodies, FOLFIRI/FOLFOXIRI: 5-FU + irinotecan, FOLFIRINOX: 5-FU + oxaliplatin + leucovorin + irinotecan, CF: 5-FU + cisplatin, FLOT: 5-FU + oxaliplatin + leucovorin + docetaxel, ECF: 5-FU + cisplatin + etoposide, DCFm: 5-FU + cisplatin + docetaxel, 5-FU + gemcitabine, 5-FU + oxaliplatin, 5-FU + docetaxel/cisplatin, 5-FU + cisplatin + trastuzumab, CEF: 5-FU + cyclophosphamide + epi-adriamycin.

^b Capecitabine-based regimens include CAPOX / CAPEOX / XELOX: capecitabine + oxaliplatin, EOX: capecitabine + oxaliplatin + epirubicin, DOX: capecitabine + oxaliplatin + docetaxel.

^c Tegafur-based regimens include tegafur + uracil + oxaliplatin.

^d The cohort study by Maharjan et al 2019 [63] included patients of a range of ethnicities (Caucasian, African American, Asian, Hispanic, and Native American). Only data from patients of African American ancestry with severe fluoropyrimidine-related toxicity (grade ≥3) were extracted and presented in this table.

Table 2. Patient characteristics.

	All	African American	East Asian	Latin American	Middle Eastern	South Asian
Patients (n) ^a	1431	25	1077	32	73	224
Age range (years)	15-90	21-90	22-81	28-77	25-79	15-82
Gender (% Male)	62	55	58	59	53	66
Cancer type (n)						
Gastrointestinal	1368	25	1028	32	73	210
Colorectal	1336	25	1028	0	73	210
Gastric	32	0	0	32	0	0
Breast	42	0	40	0	0	2
Head and Neck	21	0	9	0	0	12
Chemotherapy regimen (n)						
5-FU based	1122	25	872	29	70	126
FOLFOX / mFOLFOX6 / FOLFOX4 ^b	640	3	531	20	15	71
Other ^c	482	22	341	9	55	55
Capecitabine based	309	0	205	3	3	98
CAPOX / CAPEOX / XELOX ^d	171	0	120	3	1	47
Other ^e	138	0	85	0	2	51
Tegafur based ^f	1	0	0	0	0	1
Severe toxicity manifestations events (n)						
Haematological ^g	261	7	111	18	106	19
Gastrointestinal ^h	229	18	108	14	17	72
Dermatological ⁱ	47	6	11	8	5	17
Hepatotoxicity ^j	14	0	5	0	9	0
Neurotoxicity ^m	7	2	0	3	2	0
Renal toxicity ^p	10	0	0	0	10	0
Fluoropyrimidine dose modification (n)	31	1	0	0	1	29
Fluoropyrimidine discontinuation (n)	8	1	0	0	1	6
DPYD variants (n)	53	19	30	3	13	7
DPYD haplotypes (n)	26	2	17	4	2	5
DPD activity (n)						
PBMCs	3	0	3	0	0	0
Plasma UH2/U ratio	2	0	1	0	1	0

5-FU: 5-fluorouracil; DPYD: Dihydropyrimidine dehydrogenase gene; DPD: Dihydropyrimidine dehydrogenase; PBMCs: peripheral blood mononuclear cells; UH2/U: dihydrouracil/uracil plasma ratio.

^a Number of patients who developed fluoropyrimidine-related severe toxicity (grade ≥3).

^b FOLFOX / mFOLFOX6 / FOLFOX4: 5-FU + oxaliplatin + leucovorin.

^c 5-FU combined with: cisplatin; cisplatin + docetaxel; cisplatin + etoposide; oxaliplatin + leucovorin + docetaxel; irinotecan; oxaliplatin + irinotecan + leucovorin; irinotecan + anti-VEGF/anti-EGFR antibodies; gemcitabine; oxaliplatin; docetaxel/cisplatin; cisplatin + trastuzumab; cyclophosphamide + epirubicin; oxaliplatin + leucovorin.

^d CAPOX / CAPEOX / XELOX: capecitabine + oxaliplatin.

^e Capecitabine combined with: oxaliplatin + docetaxel; oxaliplatin + epirubicin.

^f Tegafur combined with: oxaliplatin + uracil.

^g Haematological toxicity: anaemia, leukopenia, neutropenia, thrombocytopenia, myelosuppression/bone marrow toxicity, haemorrhage, thrombosis, pancytopenia.

^h Gastrointestinal toxicity: diarrhoea, mucositis, vomiting, nausea, mucosal damage.

ⁱ Dermatological toxicity: hand-and-foot syndrome, alopecia, stomatitis, skin ulceration.

^j Hepatotoxicity: hepatotoxicity and liver function damage.

^m Neurotoxicity: neurotoxicity and peripheral neuropathy.

^p Renal toxicity: renal dysfunction and proteinuria.

Table 3: *In silico* predictions of *DPYD* variants evaluated in our systematic review.

Chr:BP (GRCh38)	dbSNP rsID	HGVS nomenclature	Location, Molecular consequence	CPIC Phenotype ^a : Ref/Alt, Alt/Alt, (LoE)	<i>In silico</i> prediction undertaken				Published <i>in silico</i> predictions			Published <i>in vitro</i> data ^g
					Protein function/ structure ^b	Splicing ^c	Transcription factor binding ^d	miRNA binding ^e	Published <i>in silico</i> protein function/ structure prediction	DPYD- varifier ^f	APF ^f	
1:97921479	rs72981745	1:n.688+20094C>T	5'US		B (3 of 3)	B (3 of 3)	TF (1 of 3) NTF (2 of 3)	N/A				
1:97886497	rs4970722	c.40-3123T>A	Intron 1		N/A	SC (2 of 9) NSC (7 of 9)	N/A	N/A				
1:97883352	rs80081766	c.62G>A, Arg21Gln	Exon2, Missense	NM, NM (M)	D (7 of 13) PD (1 of 13) B (5 of 13)	SC (6 of 9) NSC (3 of 9)	N/A	N/A				N (1 of 1)
1:97883329	rs1801265	c.85T>C, Cys29Arg, *9A	Exon2, Missense	NM, NM (H)	D (1 of 11) B (10 of 11)	SC (2 of 9) NSC (7 of 9)	N/A	N/A	B (0) / B (0.18) ^p		N	I (1 of 3) R (2 of 3)
1:97740456	rs568132506	c.257C>T, Pro86Leu	Exon 4, Missense		D (12 of 13) PD (1 of 13)	SC (7 of 9) NSC (2 of 9)	N/A	N/A				SR (1 of 1)
1:97740411- 97740418	rs72549309	c.295_298delTCAT, Phe100fs, *7	Exon 4, Frameshift	IM, PM (M)	D (3 of 3)	SC (2 of 5) NSC (3 of 5)	N/A	N/A			D	LoF (1 of 1)
1:97740390	rs1193078195	c.321+2T>C	Intron 4, Splice donor		D (6 of 6)	SC (8 of 9) NSC (1 of 9)	N/A	N/A	D ⁱ			
1:97721542	rs200562975	c.451A>G, Asn151Asp	Exon 5, Missense	NM, NM (W)	D (11 of 13) PD (1 of 13)	SC (5 of 9) NSC (4 of 9)	N/A	N/A			D	N (1 of 3) I (1 of 3) R (1 of 3)
1:97721529	rs2101026231	c.464T>A, Leu155Ter	Exon 5, Nonsense		D (5 of 7) PD (1 of 7) B (1 of 7)	SC (6 of 4) NSC (1 of 7)	N/A	N/A				
1:97699535	rs2297595	c.496A>G, Met166Val	Exon 6, Missense	NM, NM (M)	D (8 of 13) PD (1 of 13) B (4 of 13)	SC (4 of 9) NSC (5 of 9)	N/A	N/A	D (1) / B (0.07) ^p		D	I (1 of 3) R (2 of 3)
1:97699474	rs115232898	c.557A>G, Tyr186Cys	Exon 6, Missense	IM, IM (M)	D (9 of 13) PD (1 of 13) B (3 of 13)	SC (5 of 9) NSC (4 of 9)	N/A	N/A			D	R (1 of 1)
1:97699435	rs776973423	c.596G>A, Ser199Asn	Exon 6, Missense		D (11 of 13) PD (1 of 13) B (1 of 13)	SC (5 of 9) NSC (4 of 9)	N/A	N/A	D (1) / D (0.02) ^p		D	
1:97699212	rs6668296	c.680+139G>A	Intron 6		N/A	SC (1 of 9) NSC (8 of 9)	N/A	N/A				
1:97691827	rs376597772	c.681-29G>T	Intron 6		N/A	SC (1 of 9) NSC (8 of 9)	N/A	N/A				
1:97691775	rs755416212	c.704G>A, Arg235Gln	Exon 7, Missense		D (12 of 13) PD (1 of 13)	SC (6 of 9) NSC (3 of 9)	N/A	N/A	D ^k		D	
1:97691746	rs767836989	c.733A>G, Ile245Val	Exon 7, Missense		D (2 of 13) B (11 of 13)	SC (3 of 9) NSC (6 of 9)	N/A	N/A	PD (0.853) / D (0) ^p		N	
1:97679300	rs3790387	c.763-118A>G	Intron 8		N/A	SC (2 of 9) NSC (7 of 9)	N/A	N/A				
1:97613437	rs2811196	c.851-18271A>G	Intron 9		N/A	NSC (9 of 9)	N/A	N/A				

1:97593379	rs201018345	c.967G>A, Ala323Thr	Exon 10, Missense	NM, NM (W)	D (2 of 13) PD (1 of 13) B (10 of 13)	SC (3 of 9) NSC (6 of 9)	N/A	N/A		N (1 of 1)
1:97593343	rs72549306	c.1003G>T, Val335Leu, *11	Exon 10, Missense	NM, NM (M)	D (11 of 13) PD (1 of 13) B (1 of 13)	SC (6 of 9) NSC (3 of 9)	N/A	N/A	D (1) / D (0) ^P	N (1 of 1)
1:97573985	rs56293913	c.1129-15T>C	Intron 10		N/A	NSC (9 of 9)	N/A	N/A		
1:97573943	rs78060119	c.1156G>T, Glu386Ter, *12	Exon 11, Nonsense	IM, PM (M)	D (7 of 7)	SC (6 of 9) NSC (3 of 9)	N/A	N/A		LoF (1 of 1)
1:97573863	rs56038477	c.1236G>A, Glu412=	Exon 11, Synonymous	IM, IM (H)	D (3 of 6) B (3 of 6)	SC (2 of 9) NSC (7 of 9)	N/A	N/A		
1:97561245	rs2811219	c.1340-11501T>C	Intron 12		N/A	SC (1 of 9) NSC (8 of 9)	N/A	N/A		
1:97515952	rs55699321	c.1525-11G>A	Intron 12		N/A	NSC (9 of 9)	N/A	N/A		
1:97515950	rs56056384	c.1525-9A>G	Intron 12		N/A	NSC (9 of 9)	N/A	N/A		
1:97515865	rs1801158	c.1601G>A, Ser534Asn, *4	Exon 13, Missense	NM, NM (M)	D (8 of 12) PD (1 of 12) B (3 of 12)	SC (6 of 9) NSC (3 of 9)	N/A	N/A	D (False positive) ^Q	I (1 of 2) R (1 of 2)
1:97515851	rs142619737	c.1615G>C, Gly539Arg	Exon 13, Missense	NM, NM (W)	D (12 of 13) B (1 of 13)	SC (4 of 9) NSC (5 of 9)	N/A	N/A		N (2 of 2)
1:97515839	rs1801159	c.1627A>G, Ile543Val, *5	Exon 13, Missense	NM, NM (H)	D (1 of 13) B (12 of 13)	SC (2 of 9) NSC (7 of 9)	N/A	N/A	B (0) / B (0.44) ^P	N N (2 of 3) R (1 of 3)
1:97515787	rs55886062	c.1679T>G, Ile560Ser, *13	Exon 13, Missense	IM, PM (M)	D (11 of 13) PD (1 of 13) B (1 of 13)	SC (5 of 9) NSC (4 of 9)	N/A	N/A	D	I (1 of 2) R (1 of 2)
1:97515754	rs1195493601	c.1712C>A, Ala571Asp	Exon 13, Missense		D (7 of 9) B (2 of 9)	SC (3 of 7) NSC (4 of 7)	N/A	N/A	D (1) / D (0) ^P	
1:97515729		c.1737T>C, Asp579Asp	Exon 13, Synonymous		N/A	SC (1 of 7) NSC (6 of 7)	N/A	N/A		
1:97515583		g.97515583_975155 84insA	Intron 13, Insertion		U/N	U/N	U/N	U/N	PD ^m	
1:97515686	rs2811178	c.1740+40A>G	Intron 13		N/A	NSC (7 of 7)	N/A	N/A	PD ^m	
1:97515687	rs2786783	c.1740+39C>T	Intron 13		N/A	NSC (7 of 7)	N/A	N/A	PD ^m	
1:97450190	rs59086055	c.1774C>T, Arg592Trp	Exon 14, Missense	IM, PM (W)	D (12 of 13) PD (1 of 13)	SC (6 of 9) NSC (3 of 9)	N/A	N/A	D	SR (3 of 3)
1:97450101	rs1057516388	c.1863G>T, Trp621Cys	Exon 14, Missense		D (9 of 9)	SC (6 of 8) NSC (2 of 8)	N/A	N/A	D (1) / D (0) ^P	
1:97450068	rs17376848	c.1896T>C, Phe632=	Exon 14, Synonymous	NM, NM (M)	B (5 of 5)	NSC (9 of 9)	N/A	N/A		
1:97450066- 97450067	rs72549303	c.1898delC, Pro633fs, *3	Exon 14, Frameshift	IM, PM (M)	D (4 of 4)	SC (3 of 6) NSC (3 of 6)	N/A	N/A	D	LoF (1 of 1)
1:97450058	rs3918290	c.1905+1G>A, *2A	Intron 14, Exon 14 skipping, Splice donor	IM, PM (H)	D (6 of 6)	SC (7 of 9) NSC (2 of 9)	N/A	N/A		LoF (1 of 1)

1:97410967	rs4492658	c.1906-28506C>G	Intron 14		N/A	SC (1 of 7) NSC (6 of 7)	N/A	N/A			
1:97382584	rs56279424	c.1906-123C>A	Intron 14		N/A	NSC (7 of 7)	N/A	N/A			
1:97382318	rs72728438	c.1974+75T>C	Intron 15		N/A	SC (2 of 8) NSC (6 of 8)	N/A	N/A			
1:97305364	rs1801160	c.2194G>A, Val732Ile, *6	Exon 18, Missense	NM, NM (M)	D (6 of 12) PD (1 of 12) B (5 of 12)	SC (4 of 9) NSC (5 of 9)	N/A	N/A	D (0.999) / D (0) ^p	N	N (1 of 4) I (2 of 4) R (1 of 4)
1:97234991	rs56005131	c.2303C>A, Thr768Lys	Exon 19, Missense	NM, NM (W)	D (8 of 13) PD (1 of 13) B (4 of 13)	SC (4 of 9) NSC (5 of 9)	N/A	N/A	B (0) / B (0.18) ^p	D	N (1 of 2) R (1 of 2)
1:97234860	rs371313778	c.2434G>A, Val812Ile	Exon 20, Missense		D (4 of 13) PD (1 of 13) B (8 of 13)	SC (3 of 9) NSC (6 of 9)	N/A	N/A			
1:97098452	rs199712715	c.2766+37T>C	Intron 22		N/A	NSC (9 of 9)	N/A	N/A			
1:97079215	rs290855	c.2908-69A>G	Intron 22		N/A	NSC (9 of 9)	N/A	N/A			
		IVS22+585C>T	Intron 22		N/A	N/A	N/A	N/A			
		IVS23-69A>G	Intron 23		N/A	N/A	N/A	N/A			
1:97078208	rs291592	c.*768G>A	3' UTR		N/A	NSC (6 of 6)	N/A	miR (2 of 2)			
1:97073844	rs76387818	c.*5132C>T	~4kb 3' of DPYD		N/A	SC (3 of 7) NSC (4 of 7) ^h	N/A	N/A			
1:97057448	rs12132152	c.*21528C>T	~20kb 3' of DPYD		N/A	SC (3 of 7) NSC (4 of 7) ^h	N/A	N/A			

CPIC: Clinical Pharmacogenetics Implementation Consortium; *DPYD*: Dihydropyrimidine dehydrogenase gene; HGVS: Human Genome Variation Society; N/A: not applicable

^a Likely *DPYD* phenotype based on *DPYD* genotype in accordance with the CPIC guideline for fluoropyrimidines and *DPYD*. **Ref/Alt**: heterozygous variant carrier; **Alt/Alt**: homozygous carrier for the alternative variant; **NM**: Normal Metabolizer; **IM**: Intermediate Metabolizer; **PM**: Poor Metabolizer. Levels of evidence (LoE) linking *DPYD* genotype to *DPYD* phenotype assigned by CPIC. **H**: High; **M**: Moderate; **W**: Weak

^b Effect on DPD protein function or structure was predicted by Sorting Intolerant From Tolerant (SIFT), Polymorphism Phenotyping v2 (PolyPhen-2), MutPred2, Mendelian Clinically Applicable Pathogenicity (M-CAP), Cancer-Related Analysis of Variants Tool (CRAVAT), Rare Exome Variant Ensemble Learner (REVEL), MutationAssessor, MetaLR, Functional Analysis Through Hidden Markov Models (FATHMM), MutationTaster, MutationTaster2021, Combined Annotation Dependent Depletion (CADD) and PredictSNP2. *In silico* prediction scores were assigned as follows: **D** = deleterious/damaging/pathogenic/diseasing causing/ likely diseasing causing; **PD** = probably damaging/medium/possibly pathogenic; **B** = benign/low/tolerated/likely benign.

^c Effect on splicing was predicted using SpliceAI, Human Splicing Finder (HSF), NNSplice, SpliceRover, Functional Analysis Through Hidden Markov Models (FATHMM), MutationTaster, MutationTaster2021, Combined Annotation Dependent Depletion (CADD) and PredictSNP2. *In silico* prediction results were summarised as follows: **SC** = Change in splicing; **NSC** = No change in splicing.

^d Effect on transcription factor binding was predicted using PROMO, SNP2TFBS and sTRAP. *In silico* prediction results were summarised as follows: **TF** = change in transcription factor binding; **NTF** = No change in transcription factor binding.

^e Effect on binding affinity for target miRNAs was predicted using the PolymiRTS database and MicroSNIper. *In silico* prediction results were summarised as follows: **miR** = miRNA binding site created.

^f Published data from previously developed *in silico* functional prediction models, DPYD-varifier (Shrestha *et al.*, 2018) and the ADME-optimised Prediction Framework (APF) (Zhou *et al.*, 2019 [55], Zhou *et al.*, 2020 [54]) were extracted. *In silico* prediction scores were assigned as follows: **D** = Deleterious; **N** = Normal/Neutral.

^g Published functional data on DPD enzyme activity from *in vitro* experiments transiently expressed with *DPYD* variants using HEK293T/c17 cells treated with 5-FU, HEK293T Flp-In cells treated with thymine and 293FT cells with 5-FU were reported (Offer *et al.*, 2013 [56], Offer *et al.*, 2014 [57], Kuilenburg *et al.*, 2016 [58], Elraiyah *et al.*, 2017 [42], Hishinuma *et al.*, 2018 [45], Hishinuma *et al.*, 2020 [65], Hishinuma *et al.*, 2022 [59]). The scores were assigned as follows: **LoF** = Loss of function; **SR** = Significantly reduced; **R** = Reduced; **I** = Increased; **N** = Normal.

^h *In silico* prediction was performed using *DPYD* intron 22 variant rs142861208 which is in perfect LD ($r^2 = 1$) with identified variant.

ⁱ Predicted using Human Splicing Finder (Tong *et al.*, 2018 [72]).

^k Predicted using DPYD-varifier (Ly *et al.*, 2020 [90]).

^m Predicted using MutationTaster and PolyPhen-2 (Almashagbah *et al.*, 2022 [81]).

^p Predicted using Polyphen-2 and SIFT (Yokoi *et al.*, 2020 [48]).

^q Identified as false positive by authors of APF (Zhou *et al.*, 2019 [55]).

Identification

Records identified from:
MEDLINE (PubMed) (n=447)
Web of Science (n=1355)
Embase (OVID) (n=3192)
Scopus (n=5316)

Screening

2178 duplicate records removed

8132 records screened on basis of title
and abstract
(Includes 18 conference abstracts and 3
non-English articles)

8052 records excluded (eligibility criteria not met)

80 full-text articles screened

1 additional record
identified through
reference list

49 full-text articles excluded
Non-clinical research articles (n=9)
No *DPYD* genotyping involved (n=26)
Severity of FP-related toxicity not assessed (n=5)
Overlapping data from same patient cohort (n=1)
Unable to extract data (n=8)

Included

32 studies included in
systematic review

